RARECast
En podcast av RARECast - Torsdagar
548 Avsnitt
-
How One Drugmaker Reaches out to Communities at Greater Risk for Rare Heart Condition
Publicerades: 2023-03-03 -
A Next-Generation RNA Therapy Targets Telomere Disorders
Publicerades: 2023-03-03 -
BridgeBio Advances Therapy for Limb-Girdle Muscular Dystrophy that Started with Two Patient Families
Publicerades: 2023-02-24 -
Translating Urgency into Science
Publicerades: 2023-02-16 -
Empowering Ultra-Rare Disease Patients to Pursue the Discovery of Treatments
Publicerades: 2023-02-10 -
Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X
Publicerades: 2023-02-02 -
An Ultra-Rare Disease Drug Developer Tries to Navigate Regulatory Uncertainty
Publicerades: 2023-01-26 -
Powering Cells in People with Rare Mitochondrial Diseases
Publicerades: 2023-01-19 -
Powering Weakened and Stressed Cells in ALS to Function Better with Nanocrystal Therapy
Publicerades: 2023-01-12 -
Developing a New Class of Therapies Based on a Natural Cargo Carrier
Publicerades: 2023-01-05 -
Reaching Beyond the Limits of Enzyme Replacement Therapies with Gene Therapies
Publicerades: 2022-12-29 -
One Woman’s Journey as a Caregiver to a Husband with Frontotemporal Dementia
Publicerades: 2022-12-22 -
Treating Rare Endocrine Disorders with Therapeutic Peptides
Publicerades: 2022-12-15 -
Tackling the Pricing Challenges for Advanced Therapies for Rare Diseases
Publicerades: 2022-12-08 -
Addressing the Current Limitations of AAV Gene Therapies
Publicerades: 2022-12-01 -
Examining the Legislative Landscape for Rare Disease Drug Development
Publicerades: 2022-11-24 -
How a Drug Setback Became a Patient Community’s Gain
Publicerades: 2022-11-18 -
Helping Regulators and Drug Developers Understand the Challenges of Living with Fabry Disease
Publicerades: 2022-11-10 -
Addressing Racial Disparities in a Rare Blood Cancer
Publicerades: 2022-11-03 -
How New Sequencing Technology Promises to Alter the Diagnostic Odyssey
Publicerades: 2022-10-27
RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.
